POLYPHENOLIC WEALTHY MORINGA LEAVES EXTRACTS AS ANTICOXSACKIE B VIRUSES (COX-BV)

The antiviral role of Moringaoleifera leaves extracts ((chloroform (CL), Ethyl acetate (E.A), methanol 80% (M) and n.butanol (n.b) to control Coxsackie B (COX-BV) viral infection was monitored in vitro compared with human interferon alpha (IFNᾰ2a) in order to evaluate the antiviral activity of morin...

Full description

Bibliographic Details
Main Authors: Naglaa Saif, B. Othman, A. Mohamed, Kh. El-Dougdoug
Format: Article
Language:Arabic
Published: The Union of Arab Universities 2019-03-01
Series:Arab Universities Journal of Agricultural Sciences
Subjects:
Online Access:https://ajs.journals.ekb.eg/article_43350_b8b6b54e29995218937738494969a141.pdf
Description
Summary:The antiviral role of Moringaoleifera leaves extracts ((chloroform (CL), Ethyl acetate (E.A), methanol 80% (M) and n.butanol (n.b) to control Coxsackie B (COX-BV) viral infection was monitored in vitro compared with human interferon alpha (IFNᾰ2a) in order to evaluate the antiviral activity of moringa leaves extracts. The phenolic compound was given higher conc. in E.A. extracts. Cytotoxicity was determined for Moringa leaves extracts on viability of HEP2 cell using MTT assay. The 98μg/ml concentrations for four extracts were considerably non-toxic for HEP2 cell line culture. Antiviral activity in Moringa extracts may be attributed to phenolic compounds and / or as a result of stimulation of COX-BV-sensitive HEP2 cells to express MX protein. Antiviral activity of Moringa leaves extracts compared with IFNᾰ-2a to cell lines against COX-BV viral infection was determined by assessment of the COX-BV virus infectivity titer declining rate and relative residual living cell count using End Point Assay, using three ways pretreatment, co-treatment and post-treatment cell line treated with Moringaextracts. It was found that the extract acetyl acetate was better as an MX gene expression level compared with its level in control cells. It was concluded that Moringaleaves extracts have antiviral activity against COX-BV.
ISSN:1110-2675
2636-3585